scispace - formally typeset
S

Shohei Eto

Researcher at Hiroshima University

Publications -  4
Citations -  274

Shohei Eto is an academic researcher from Hiroshima University. The author has contributed to research in topics: Osteogenesis imperfecta & KRAS. The author has an hindex of 1, co-authored 4 publications receiving 37 citations.

Papers
More filters
Journal ArticleDOI

Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

Paul Bastard, +58 more
- 19 Aug 2021 - 
TL;DR: In this paper, the authors found that auto-antibodies neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections.
Journal ArticleDOI

Cyclic intravenous pamidronate in a very low-birthweight infant with osteogenesis imperfecta.

Shohei Eto, +4 more
- 01 May 2018 - 
TL;DR: The experience of successful pamidronate therapy for a preterm infant with severe OI and birthweight <1,500 g is reported on, which is widely used in affected children with OI.
Journal Article

Autoantibodies neutralizing type I IFNs are present in similar to 4% of uninfected individuals over 70 years old and account for similar to 20% of COVID-19 deaths

Paul Bastard, +194 more
- 01 Jan 2021 - 
Journal ArticleDOI

MSH2 deletion with CREBBP and KRAS mutations in pediatric high-hyperdiploid acute lymphoblastic leukemia.

Jun Ichi Ueyama, +4 more
- 30 Aug 2017 - 
TL;DR: The present case has shown that PBSI involving two bacterial strains (S. pneumoniae and H. influenzae) simultaneously is possible in a previously healthy child, and demonstrates that PBSi should be considered even in previously healthy children.